Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01869192 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial for Large ER-Negative Breast Cancers
A Phase 2 study of Malignant Neoplasm of Female Breast, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT01869192 is a Phase 2 study of Malignant Neoplasm of Female Breast that has completed, run by University of Colorado, Denver. The registered enrollment target is 72 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01869192, a Phase 2 study of Malignant Neoplasm of Female Breast, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
A primary objective of this study is to evaluate the in vivo response of tumor to chemotherapy through gene microarray analysis. Neoadjuvant treatment allows the unique opportunity to observe the in vivo effects of cytotoxic therapy on gene expression in tumor tissue. The investigators plan to evaluate several different questions by comparing gene profiles in different phases of treatment in this study. These are outlined below. Hypotheses 1. Chemotherapy enriches for tumor cell populations that have enhanced resistance and survival mechanisms. These mechanisms will in part be identifiable through changes in gene expression profiles pre vs. post treatment. 2. Use of two distinct chemotherapy selection pressures, for example a DNA-damaging regimen (epirubicin and cyclophosphamide) or a mitotic spindle/metabolic targeted regimen (docetaxel and capecitabine), will allow for the identification of a smaller set of genes associated to resistance and survival mechanisms of broad importance. 3. Genes associated with enrichment for resistance and survival mechanisms will not be present in large amounts pretreatment in tumors destined for complete pathologic response.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Docetaxel
- DRUG Capecitabine
- RADIATION Radiation Therapy
- DRUG Epirubicin
Study Locations (1)
Colorado
- University of Colorado Cancer Center - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2003-03-05 |
| Est. Completion | 2010-08-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01869192
The ClinicalTrials.gov registry entry for NCT01869192 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Neoplasm of Female Breast appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01869192 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT01869192 about?
NCT01869192 is a clinical study titled "Phase II Trial for Large ER-Negative Breast Cancers". A primary objective of this study is to evaluate the in vivo response of tumor to chemotherapy through gene microarray analysis. Neoadjuvant treatment allows the unique opportunity to observe the in vivo effects of cytotoxic therapy on gene expression in tumor tissue. The investigators plan to evalu...
What is the current status of trial NCT01869192?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2003-03-05. Estimated completion is 2010-08-21.
What conditions does trial NCT01869192 study?
This clinical trial studies the following conditions: Malignant Neoplasm of Female Breast.
What interventions are being tested in trial NCT01869192?
The interventions under investigation include: Cyclophosphamide (DRUG), Docetaxel (DRUG), Capecitabine (DRUG), Radiation Therapy (RADIATION), Epirubicin (DRUG).
Who is sponsoring clinical trial NCT01869192?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01869192 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.